UTHR Q3 2019 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$402M-2.7% YoY

Gross Profit

$369M91.8% margin

Operating Income

$183M45.7% margin

Net Income

$132M33.0% margin

EPS (Diluted)

$3.01

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$185M

Free Cash Flow

$172M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$1.3B

Stockholders' Equity

$2.7B

Cash & Equivalents

$720M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$402M	$413M	-2.7%
Gross Profit	$369M	$361M	+2.1%
Operating Income	$183M	$150M	+22.6%
Net Income	$132M	$107M	+24.3%

Revenue Segments

Remodulin

$168M42%

Tyvaso

$111M28%

Orenitram

$62M15%

Adcirca

$30M8%

Unituxin

$30M7%

Geographic Segments

U

$359M90%

European Union And Others

$42M10%